ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

VSTM vs RAPP // EV/EBITDA & P/E VALUATION

Verastem Inc. (NASDAQ) VS. Rapport Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: VSTM 3 — RAPP 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VSTM VS. RAPP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC VSTM RAPP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -22.90% -12.10 RAPP /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -11.72% -7.58% -4.14 RAPP /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 VSTM /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 61.7 37.5 +24.12 VSTM /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.17B $1.16B $11.4M VSTM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR VSTM REV RAPP REV VSTM GROSS % RAPP GROSS % VSTM FCF RAPP FCF
FY 2025 $30.9M $0 — — -$137.5M -$88.1M
FY 2024 $10.0M $0 — — -$104.8M -$67.2M
FY 2023 $0 $0 — — -$86.5M -$27.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VSTM // BETA —
RAPP // BETA —